<DOC>
	<DOCNO>NCT02063607</DOCNO>
	<brief_summary>This open label , dose ranging , phase1a/1b clinical trial study safety , Pharmacokinetics Pharmacodynamics Peglamda 60 , 120 , 180 240 mcg healthy volunteer antiviral activity weekly Peglamda administration combination daily Ribavirin Hepatitis C naive patient 4 week period . The objective study establish safety , PK/PD data healthy subject preliminary efficacy safety Hepatitis C naive patient .</brief_summary>
	<brief_title>The Study Safety , Pharmacokinetics , Pharmacodynamics Peglamda ( Peginterferon Lamda 1 ) Healthy Volunteers Preliminary Evaluation Peglamda Hepasig ( Ribavirin ) Treatment 's Effects Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Phase 1a : The subject willing participate Phase 1a study must meet ALL follow inclusion criterion : 1 . Volunteers ( male female ) age 1845 2 . Women negative pregnancy test result time study . 3 . Clinical examination result laboratory 7 day start trial must inside normal range . 4 . Currently follow treatment regimen ( except use oral contraceptive ) . 5 . Body mass index range / 25 % difference compare normal BMI ( Appendix 6 ) . 6 . Be able comply protocol exchange information effectively researcher , agree write informed consent participate clinical trial Phase 1b : Subjects willing participate phase 1b study must meet ALL follow inclusion criterion : 1 . Patients chronic hepatitis C ( male female ) . 2 . Ages 18 65 year old . 3 . Female patient ( female partner male patient ) negative pregnancy test result and/or apply effective contraception still sex study 6 month use last dose Ribavirin . 4 . No previous treatment IFN IFN treatment rapid viral response already completely viral response leave treatment early . 5 . HCVRNA level serum &gt; 80 IU / mL . 6 . The haematological biochemical ( except ALT / AST ) parameter must within normal limit . 7 . Body weight normal range 25 % difference compare normal BMI ( Appendix 6 ) 8 . Be able comply protocol exchange information effectively researcher , agree write informed consent participate clinical trial Phase 1a : Subjects least 1 follow exclusion criterion consider ineligible participate Phase 1a study : 1 . With history drug abuse , alcohol drug use within 1 year take part clinical trial . AUDITC scale ( WHO ) use ass use alcohol . The score ≥ 4 men ≥ 3 woman consider alcoholic . 2 . History depression 3 . History chronic disease relate respiratory system , cardiovascular , gastrointestinal , malignant disease affect function organ system . Having interferon antiviral therapy within 4 month trial 4 . Participate clinical trial within 3 month prior test 5 . Use drug last period relatively positive test last approximately 6 time halflife drug . 6 . Blood donor 400 mL blood within 3 month prior test 7 . Influenza infection cold symptom within 2 week trial 8 . Having positive test HBV , HCV HIV 9 . Breastfeeding woman Phase 1b : Subjects least 1 follow exclusion criterion consider ineligible participate Phase 1b study : 1 . Coinfection hepatitis B and/or HIV . 2 . Hepatic Impairment 3 . Cirrhosis 4 . Positive test antibody Peginterferon lambda 1 Peginterferon alpha 2a . 5 . History chronic disease relate respiratory system , cardiovascular , gastrointestinal , malignant disease affect function organ system . 6 . A history immune disorder ( eg , inflammatory bowel disease , hemorrhagic thrombocythemia , lupus erythematosus , autoimmune hemolytic anemia , autoimmune disease , scleroderma , severe psoriasis , arthritis rheumatoid ... ) 7 . A history severe mental illness , especially depression , especially serious neurological condition determine depression serious psychological disorder , suicidal intention , hospitalize mental illness , 1 phase impaired function due neuropathy . 8 . A history severe epilepsy use antiepileptic drug . 9 . A history use anticancer agent ( include radiation therapy ) immunotherapy ( include systematic corticosteroid ) within 6 month use first test dose patient may need treatment trial 10 . History organ transplant presence graft function . 11 . Evidence alcohol drug abuse within 1 year trial . AUDIT scale C use ass use alcohol . The score ≥ 4 men ≥ 3 woman consider alcoholic 12 . History evidence severe disease condition base investigator assessment subject may suitable study . 13 . Breastfeeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hepatitis C naive</keyword>
</DOC>